TORECAN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jul 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TORECAN is an injectable small-molecule drug approved by Novartis in 1961 with an unknown mechanism of action and indication profile. The product is currently in the loss-of-exclusivity (LOE) approaching phase, indicating it is a legacy asset nearing generic competition.
LOE Approaching
Declining commercial priority with minimal team expansion as the product approaches generic conversion and market erosion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TORECAN offers limited career advancement opportunity given its LOE-approaching status and minimal linked job activity. Professionals on this product would focus on defensive strategies, generic preparation, and transition planning rather than growth initiatives.
Brand ManagerMedical Science Liaison
Worked on TORECAN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.